Transarterial administration of integrin inhibitor loaded nanoparticles combined with transarterial chemoembolization for treating hepatocellular carcinoma in a rat model

World Journal of Gastroenterology

Volumn 22, Issue 21, 2016, Pages 5042-5049

  Qian, Jun ^a   Oppermann, Elsie ^b   Tran, Andreas ^b   Imlau, Ulli ^b   Qian, Kun ^a   Vogl, Thomas Josef ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

ACI rats; Hepatocellular carcinoma; Integrin inhibitor; Matrix metalloprotein 9; Nanoparticles; Transarterial chemoembolization; Vascular endothelial growth factor

Indexed keywords

GELATINASE B; GLYCYLARGINYLGLYCYLASPARTYLSERYLPROLINE; IODINATED POPPYSEED OIL; MICROSPHERE; MITOMYCIN; NANOPARTICLE; VASCULOTROPIN; ANTINEOPLASTIC AGENT; ETHIODIZED OIL; GLYCYL-ARGINYL-GLYCYL-ASPARTYL-SERYL-PROLINE; INTEGRIN; MMP9 PROTEIN, RAT; OLIGOPEPTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHEMOEMBOLIZATION; CONTROLLED STUDY; CYTOPLASM; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MALE; METASTASIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; STAINING; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; AUGUST COPENHAGEN IRISH RAT; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG EFFECTS; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER NEOPLASMS, EXPERIMENTAL; METABOLISM; NANOMEDICINE; PATHOLOGY; PROCEDURES;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CHEMOEMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; HEPATIC ARTERY; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRA-ARTERIAL; INTEGRINS; LIVER NEOPLASMS, EXPERIMENTAL; MAGNETIC RESONANCE IMAGING; MALE; MATRIX METALLOPROTEINASE 9; NANOMEDICINE; NANOPARTICLES; OLIGOPEPTIDES; RATS, INBRED ACI; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84978792111     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i21.5042     Document Type: Article

References (30)

1. Chen X, Liu HP, Li M, Qiao L. Advances in non-surgical management of primary liver cancer. World J Gastroenterol 2014; 20: 16630-16638 [PMID: 25469032 DOI: 10.3748/wjg.v20.i44.16630]
2. Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic management of hepatocellular carcinoma. World J Gastroenterol 2015; 21: 12003-12021 [PMID: 26576088 DOI: 10.3748/wjg.v21.i42.12003]
3. Li D, Kang J, Madoff DC. Locally ablative therapies for primary and metastatic liver cancer. Expert Rev Anticancer Ther 2014; 14: 931-945 [PMID: 24746315 DOI: 10.1586/14737140.2014.911091]
4. Rou WS, Lee BS, Moon HS, Lee ES, Kim SH, Lee HY. Risk factors and therapeutic results of early local recurrence after transcatheter arterial chemoembolization. World J Gastroenterol 2014; 20: 6995-7004 [PMID: 24944494 DOI: 10.3748/wjg.v20. i22.6995]
5. Qian J, Feng GS, Vogl T. Combined interventional therapies of hepatocellular carcinoma. World J Gastroenterol 2003; 9: 1885-1891 [PMID: 12970869 DOI: 10.3748/wjg.v9.i9.1885]
6. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J, Bruix J. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-1739 [PMID: 12049862 DOI: 10.1016/s0140-6736(02)08649-x]
7. Cai W, Chen X. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism. Anticancer Agents Med Chem 2006; 6: 407-428 [PMID: 17017851 DOI: 10.2174/187152006778226530]
8. Qian J, Yin J, Liang H, Wang Y, Feng G. Experimental study on transarterial administration of GRGDSP combined with transarterial chemoembolization in rats with hepatic carcinoma. Cardiovasc Intervent Radiol 2008; 31: 377-382 [PMID: 18058171 DOI: 10.1007/s00270-007-9233-0]
9. Iwasaki Y, Ueda M, Yamada T, Kondo A, Seno M, Tanizawa K, Kuroda S, Sakamoto M, Kitajima M. Gene therapy of liver tumors with human liver-specific nanoparticles. Cancer Gene Ther 2007; 14: 74-81 [PMID: 16990844 DOI: 10.1038/sj.cgt.7700990]
10. Jain KK. Nanomedicine: application of nanobiotechnology in medical practice. Med Princ Pract 2008; 17: 89-101 [PMID: 18287791 DOI: 10.1159/000112961]
11. Chen JH, Ling R, Yao Q, Wang L, Ma Z, Li Y, Wang Z, Xu H. Enhanced antitumor efficacy on hepatoma-bearing rats with adriamycin-loaded nanoparticles administered into hepatic artery. World J Gastroenterol 2004; 10: 1989-1991 [PMID: 15222053 DOI: 10.3748/wjg.v10.i13.1989]
12. Chen JH, Wang L, Ling R, Li Y, Wang Z, Yao Q, Ma Z. Body distribution of nanoparticle-containing adriamycin injected into the hepatic artery of hepatoma-bearing rats. Dig Dis Sci 2004; 49: 1170-1173 [PMID: 15387341 DOI: 10.1023/B:DDAS.0000037807 .96064.99]
13. Yang R, Rescorla FJ, Reilly CR, Faught PR, Sanghvi NT, Lumeng L, Franklin TD, Grosfeld JL. A reproducible rat liver cancer model for experimental therapy: introducing a technique of intrahepatic tumor implantation. J Surg Res 1992; 52: 193-198 [PMID: 1538593 DOI: 10.1016/0022-4804(92)90072-8]
14. Qian J, Truebenbach J, Graepler F, Pereira P, Huppert P, Eul T, Wiemann G, Claussen C. Application of poly-lactide-co-glycolidemicrospheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma. World J Gastroenterol 2003; 9: 94-98 [PMID: 12508359 DOI: 10.3748/wjg.v9.i1.94]
15. Yang X, Hong H, Grailer JJ, Rowland IJ, Javadi A, Hurley SA, Xiao Y, Yang Y, Zhang Y, Nickles RJ, Cai W, Steeber DA, Gong S. cRGD-functionalized, DOX-conjugated, and 64Cu-labeled superparamagnetic iron oxide nanoparticles for targeted anticancer drug delivery and PET/MR imaging. Biomaterials 2011; 32: 4151-4160 [PMID: 21367450 DOI: 10.1016/j.biomaterials.2011.0 2.006]
16. Carlsson G, Gullberg B, Hafström L. Estimation of liver tumor volume using different formulas - an experimental study in rats. J Cancer Res Clin Oncol 1983; 105: 20-23 [PMID: 6833336 DOI: 10.1007/BF00391826]
17. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell 2002; 110: 673-687 [PMID: 12297042 DOI: 10.1016/S0092- 8674( 02)00971-6]
18. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25 [PMID: 1555235 DOI: 10.1016/00 92-8674(92)90115-S]
19. Jia JB, Zhuang PY, Sun HC, Zhang JB, Zhang W, Zhu XD, Xiong YQ, Xu HX, Tang ZY. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol 2009; 135: 847-854 [PMID: 19066962 DOI: 10.1007/s00432-008-0521-0]
20. Tsuchiya Y, Sawada S, Tsukada K, Saiki I. A new pseudopeptide of Arg-Gly-Asp (RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Int J Oncol 2002; 20: 319-324 [PMID: 11788895 DOI: 10.3892/ijo.20.2.319]
21. Hall H, Djonov V, Ehrbar M, Hoechli M, Hubbell JA. Heterophilic interactions between cell adhesion molecule L1 and alphavbeta3-integrin induce HUVEC process extension in vitro and angiogenesis in vivo. Angiogenesis 2004; 7: 213-223 [PMID: 15609076 DOI: 10.1007/s10456-004-1328-5]
22. Sheu JR, Lin CH, Peng HC, Huang TF. Triflavin, an Arg-Gly-Aspcontaining peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells. Proc Soc Exp Biol Med 1996; 213: 71-79 [PMID: 8820826 DOI: 10.3181/00379727-213-44038]
23. Takayama T, Suzuki N, Narukawa M, Goldberg HA, Otsuka K, Ito K. Enamel matrix derivative is a potent inhibitor of breast cancer cell attachment to bone. Life Sci 2005; 76: 1211-1221 [PMID: 15642592 DOI: 10.1016/j.lfs.2004.07.025]
24. Joshi P, Chung CY, Aukhil I, Erickson HP. Endothelial cells adhere to the RGD domain and the fibrinogen-like terminal knob of tenascin. J Cell Sci 1993; 106 (Pt 1): 389-400 [PMID: 7505785]
25. Wang Z, Chui WK, Ho PC. Design of a multifunctional PLGA nanoparticulate drug delivery system: evaluation of its physicochemical properties and anticancer activity to malignant cancer cells. Pharm Res 2009; 26: 1162-1171 [PMID: 19191012 DOI: 10.1007/s11095-009-9837-y]
26. Chen MS, Li JQ, Zhang YQ, Lu LX, Zhang WZ, Yuan YF, Guo YP, Lin XJ, Li GH. High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 2002; 8: 74-78 [PMID: 11833075 DOI: 10.3748/wjg.v8.i1.74]
27. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: a multivariate analysis of prognostic factors. J Clin Gastroenterol 1999; 28: 334-340 [PMID: 10372931 DOI: 10.1097/00004836-199906000-00010]
28. Bhattacharya S, Dhillon AP, Winslet MC, Davidson BR, Shukla N, Gupta SD, Al-Mufti R, Hobbs KE. Human liver cancer cells and endothelial cells incorporate iodised oil. Br J Cancer 1996; 73: 877-881 [PMID: 8611399 DOI: 10.1038/bjc.1996.156]
29. Kalva SP, Iqbal SI, Yeddula K, Blaszkowsky LS, Akbar A, Wicky S, Zhu AX. Transarterial chemoembolization with Doxorubicineluting microspheres for inoperable hepatocellular carcinoma. Gastrointest Cancer Res 2011; 4: 2-8 [PMID: 21464864]
30. Shen LF, Zhang YD, Shen HJ, Zeng S, Wang X, Wang C, Le Y, Shen H. Liver targeting and the delayed drug release of the nanoparticles of adriamycin polybutylcyanoacrylate in mice. Chin Med J (Engl) 2006; 119: 1287-1293 [PMID: 16919188]